{
  "docId": "019de072-e6c6-771e-b24a-5adaac3cef4b",
  "docSlug": "1c626f0801e0e9ad1e805f8e0140c291",
  "documentTitle": "Alkermes | Results Presentation Deck | 26 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 26,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 30,
  "notes": "Data cut off Oct 29, 2021. Includes specific patient outcomes for ovarian, pancreatic, and esophageal cancers.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-e6c6-771e-b24a-5adaac3cef4b/16",
  "deckHref": "/decks/019de072-e6c6-771e-b24a-5adaac3cef4b",
  "deckJsonHref": "/decks/019de072-e6c6-771e-b24a-5adaac3cef4b.json",
  "deckAnchorHref": "/decks/019de072-e6c6-771e-b24a-5adaac3cef4b#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.6,
        "x": 0.06,
        "y": 0.6
      },
      "kind": "list",
      "text": "Out of the 14 patients with platinum-resistant ovarian cancer (PROC): 2 complete responses (CR), 2 PRs (1 unconfirmed); 3 of these 4 PROC patients with objective responses had been on treatment >1 year; Median duration of response: 53.4 weeks; 6 had stable disease; Objective response rate: 28.6%; Disease control rate: 71.4%",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f0d3628b-1824-4ffc-815b-23c1caa3bccc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.06,
        "y": 0.83
      },
      "kind": "paragraph",
      "text": "Partial responses were also observed in patients with esophageal and pancreatic cancers",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca9fd76c-e6b8-411e-993c-e0407627dd94",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "For full list of prior therapies, please see ASCO 2022 presentation “Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors: ARTISTRY-1”; iPR, Immune partial response; PR, Partial response; uPR, Unconfirmed partial response; SCC, Squamous cell carcinoma; SD, Stable disease",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3272bf09-2761-42c0-ae24-1bac60307dc0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.9,
        "x": 0.05,
        "y": 0.212
      },
      "kind": "table",
      "text": "Table showing patient outcomes including tumor type, prior therapies, response, lesion decrease, time on therapy, and status.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e40d2bd2-044a-4a6b-b3da-5585fe7dfb8f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "ARTISTRY-1: IV Nemvaleukin in Combination With Pembrolizumab PD-1/L1 Unapproved Tumor Types",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0cea66d0-96ec-4802-af4b-6ba326c65467",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "2d45d669-b0ae-4579-aa30-fa93228069db",
      "evidence": "Table showing patient outcomes including tumor type, prior therapies, response, lesion decrease, time on therapy, and status.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 9,
      "beatId": "04379692-f7a3-428c-883b-94305cddc327",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "Slides 9-20 provide results from clinical trials.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 15,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "de462ce0-7910-4bf9-8add-416bb065dc4b",
      "evidence": "Slides 15-20 discuss the combination therapy.",
      "position": 1,
      "objective": "How does Nemvaleukin Alfa work in combination with Pembrolizumab?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}